Thats far higher than patients pay in Europe, where monthly doses cost about $100
Additional warnings in the FDA prescribing information include: severe gastrointestinal adverse reactions, acute kidney injury, acute gallbladder disease, acute pancreatitis, serious hypersensitivity reactions, hypoglycemia risk when used with insulin or insulin secretagogues, diabetic retinopathy complications and vision changes in patients with type 2 diabetes, depression or mood changes requiring clinical monitoring, and pulmonary aspiration risk during general anesthesia or deep sedation
As with any new drug, talk to a doctor first.
This will help you and your clinician decide on the best path forward
For patients who may not respond as well to GLP-1 medications like Semaglutide, Tirzepatide offers an alternative that leverages additional pathways in the body to promote weight loss